This study assessed the safety of the African swine fever (ASF) vaccine candidate ASFV-G-AMGF through an in vivo reversion to virulence study. Forced animal passaging led to a virus variant with transient fever and increased replication/shedding, but animals remained healthy. Genomic changes involved deletions and reorganizations in terminal regions, not affecting the recombination site. The study highlights the need for in-depth safety characterization of live ASF vaccines, suggesting further studies on long-term effects and transmission before benefit-risk analysis.
Publisher
npj Vaccines
Published On
May 29, 2023
Authors
Paul Deutschmann, Jan-Hendrik Forth, Julia Sehl-Ewert, Tessa Carrau, Elisenda Viaplana, Jose Carlos Mancera, Alicia Urniza, Martin Beer, Sandra Blome
Tags
African swine fever
ASF vaccine
safety assessment
in vivo study
virus variant
genomic changes
Related Publications
Explore these studies to deepen your understanding of the subject.
